Ixico Plc

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: GB00BFXR4C20
GBP
0.11
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared Negative results for the last 4 consecutive quarters

  • OPERATING CASH FLOW(Y) Lowest at GBP -1.58 MM
2

Risky -

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

GBP 10 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.39

stock-summary
Return on Equity

-12.58%

stock-summary
Price to Book

0.81

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.28%
0%
-9.28%
6 Months
-4.44%
0%
-4.44%
1 Year
-12.24%
0%
-12.24%
2 Years
-29.51%
0%
-29.51%
3 Years
-63.25%
0%
-63.25%
4 Years
-78.92%
0%
-78.92%
5 Years
-89.56%
0%
-89.56%

Ixico Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-5.82%
EBIT Growth (5y)
-206.81%
EBIT to Interest (avg)
-0.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.71
Tax Ratio
7.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.37%
ROE (avg)
4.19%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.00
EV to EBIT
-3.23
EV to EBITDA
-4.00
EV to Capital Employed
1.00
EV to Sales
1.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-30.87%
ROE (Latest)
-12.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Ixico Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2023 is -22.09% vs -6.52% in Sep 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2023 is -220.00% vs -33.33% in Sep 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.70",
          "val2": "8.60",
          "chgp": "-22.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.10",
          "val2": "0.70",
          "chgp": "-257.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.20",
          "val2": "1.00",
          "chgp": "-220.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-259.70%",
          "val2": "12.80%",
          "chgp": "-27.25%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Sep'23stock-summary
Sep'23
Sep'22
Change(%)
Net Sales
6.70
8.60
-22.09%
Operating Profit (PBDIT) excl Other Income
-1.10
0.70
-257.14%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-1.20
1.00
-220.00%
Operating Profit Margin (Excl OI)
-259.70%
12.80%
-27.25%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2023 is -22.09% vs -6.52% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2023 is -220.00% vs -33.33% in Sep 2022

stock-summaryCompany CV
About Ixico Plc stock-summary
stock-summary
Ixico Plc
Miscellaneous
IXICO plc is a brain health company. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose dementia and detect the underlying causes. mehealth is an online software for clinicians at the point-of-care to support decision making and improve the monitoring and treatment of patients. MyBrainBook is a digital platform to improve the quality of life and service delivery for people living with dementia and their supporters. TrialTracker is a Web-based system that allows users to track their imaging-based research study or clinical trial in real time. It is also collaborating with partners to develop companion digital health products.
Company Coordinates stock-summary
Company Details
4th Fl, Griffin Court, 15 Long Lane , LONDON None : EC1A 9PN
stock-summary
Tel: 44 20 37637499
stock-summary
Registrar Details